EUVIMEDEUVIMED entdecken
Open Access

Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the Need for Individualized Immune-Based Strategies

Hyunah Yoon iD, Liise-Anne Pirofski iD, David R Boulware iD

Clinical Infectious Diseases · 2025

DOI: 10.1093/cid/ciaf218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Hyunah Yoon und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA. Hauptthemen laut MEDLINE: Antifungal Agents, Meningitis, Cryptococcal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Irma L. and Abram S. Croll Charitable Trust, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The promising results of the AMBITION-cm trial in persons with HIV have sparked interest in treating non–HIV-associated cryptococcal meningitis with single 10-mg/kg liposomal amphotericin B, combined with oral flucytosine and fluconazole. However, caution is warranted when applying this approach to non-HIV organ transplant recipients, whose immune status may vary due to the effects of immunosuppressive drugs. In these patients, cryptococcal disease, which generally occurs after initial immunosuppressant doses are reduced, may be driven by fungal growth, an immune response to cryptococcal antigens, or both. The latter is particularly relevant as potent antimicrobial therapy can lyse Cryptococcus, releasing antigens that trigger inflammation and cause host-mediated damage. Reducing iatrogenic immunosuppression may enhance host immune responses, which, in the context of neurological infections, may be fatal. This highlights the importance of understanding the immune status of non-HIV organ transplant recipients within the context of the Damage-Response Framework to guide personalized treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsMeningitis, CryptococcalHumansAmphotericin BFluconazoleFlucytosineHIV InfectionsImmunocompromised HostImmunosuppressive AgentsPrecision Medicine

Stichwörter der Autor:innen

AMBITION-cm trialDamage-Response Frameworkcryptococcal meningitisimmune reconstitutionorgan transplant recipients

Substanzen

Amphotericin BAntifungal AgentsFluconazoleFlucytosineImmunosuppressive Agentsliposomal amphotericin B

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
  • Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.

ORCID-Profile: Hyunah Yoon, Liise-Anne Pirofski, David R Boulware

Förderung

  • NIH HHS
  • Irma L. and Abram S. Croll Charitable Trust
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • National Institutes of Health

Zitieren

APA

Yoon, H., Pirofski, L. A., & Boulware, D. R. (2025). Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the Need for Individualized Immune-Based Strategies. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf218

Vancouver

Yoon H, Pirofski LA, Boulware DR. Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the Need for Individualized Immune-Based Strategies. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf218

BibTeX
@article{Yoon2025,
  author = {Yoon, Hyunah and Pirofski, Liise-Anne and Boulware, David R},
  title = {Cryptococcal Meningitis Treatment Beyond HIV: Recognizing the Need for Individualized Immune-Based Strategies},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  doi = {10.1093/cid/ciaf218}
}
Kostenlos starten →